The New York Times analyzes the process whereby Celebrex, an arthritis drug, was promoted by Prizer despite knowing that it was no more effective or safer than other drugs. “Pfizer and its partner. Pharmacia, presented the results from the first six months of a yearlong study rather than the whole thing.” Pfizer defends its decision by saying that 33 million Americans have taken the drug.
MIA relies on the support of its readers to exist. Please consider a donation to help us provide news, essays, podcasts and continuing education courses that explore alternatives to the current paradigm of psychiatric care. Your tax-deductible donation will help build a community devoted to creating such change.